Suscriptores   Asóciese  
Textos Completos Autorizados
BIOMARCADORES RELACIONADOS CON LA PROGRESION DE LA ENFERMEDAD POR VIH

v-estudie-lo-mejor.gif
Expertos Invitados





BIOMARCADORES RELACIONADOS CON LA PROGRESION DE LA ENFERMEDAD POR VIH

(especial para SIIC © Derechos reservados)
Con la introducción de la terapia antirretroviral de gran actividad, han disminuido en forma notable la morbilidad y la mortalidad asociadas con el sida.
Autor:
Mªconcepción Romero Sánchez
Columnista Experta de SIIC

Institución:
Instituto De Biomedicina De Sevilla. Hospital Universitario Virgen Del Rocío

Artículos publicados por Mªconcepción Romero Sánchez
Coautor
Mªconcepción Romero Sánchez* 
Investigadora, Instituto De Biomedicina De Sevilla. Hospital Universitario Virgen Del Rocío, Sevilla, España*
Aprobación
21 de Enero, 2013 		Primera edición
5 de Febrero, 2013 		Segunda edición, ampliada y corregida
7 de Junio, 2021

BIOMARCADORES RELACIONADOS CON LA PROGRESION DE LA ENFERMEDAD POR VIH


Artículo completo
(castellano)
Extensión:  +/-2.75 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes
Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Farmacología, Infectología
Relacionadas: Bioquímica, Diagnóstico por Laboratorio, Inmunología



Comprar este artículo
Extensión: 2.75 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
MC Romero-Sanchez, Laboratory of Immunolovirology, Biomedicine Institute of Seville, Service of Infectious Disease Virgen del Rocio University Hospital, Sevilla, España
Bibliografía del artículo
1. Asmuth DM, et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 54:394-397, 2010.
2. Badley AD, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 6:420-432, 1999.
3. Baker JV, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 56:36-43, 2011.
4. Boulware DR, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203:1637-1646, 2011.
5. Bucy RP, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 103:1391-1398, 1999.
6. Cao W, et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 50:137-147, 2009.
7. Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732, 2005.
8. Ferrando Martínez S, Ruiz Mateos E, Leal M. CD27 and CCR7 expression on naive T cells, are both necessary? Immunol Lett 127:157-158, 2010.
9. Franco JM, et al1999. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 18:733-736, 1999.
10. Funderburg N, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 5:e13188.doi:10.1371/journal.pone.0013188, 2010.
11. Genebat M, et al. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother 64:845-849, 2009.
12. Giorgi JV, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179:859-870, 1999.
13. Giorgi JV, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 6:904-912, 1993.
14. Gutierrez C, et al. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One 6:e27864. doi:10.1371/journal.pone.0027864, 2011.
15. Hazenberg MD, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95:249-255, 2000.
16. Kuller LH, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5:e203.doi:10.1371/journal.pmed.0050203, 2008.
17. Liu Z, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16:83-92, 1997.
18. Palella FJ Jr, et al. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25:1865-1876, 2011.
19. Palella FJ Jr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860, 1998.
20. Pulido I, et al. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. J Infect 64:417-423, 2012.
21. Rossi R, et al. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J Acquir Immune Defic Syndr 54:e13-e14, 2010.
22. Ruiz Mateos E, et al. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors. Antimicrob Agents Chemother 55:4664-4669, 2011.
23. Saag M, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 199:1638-1647, 2009.
24. Sandler NG, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203:780-790, 2011.
25. Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials 11:351-358, 2010.
Título español
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

  English title
  Abstract
  Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia
Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517